INAB

IN8BIO, INC. (INAB) - 2025 Annual Report (10-K) Summary

Business Context and Reporting Period

Company: IN8BIO, INC.
Reporting Period: Fiscal year ended December 31, 2025.
Business Model: Clinical-stage biopharmaceutical company developing gamma-delta T cell therapies and T cell engagers (TCEs) for cancer and autoimmune diseases via its proprietary DeltEx platform.
Key Status: The company has no approved products and has not generated any revenue. It is classified as an Emerging Growth Company and a Smaller Reporting Company.

Key Financial Metrics

Note: All share and per-share data have been restated to reflect a 1-for-30 reverse stock split effective June 5, 2025.

Material Changes vs. Prior Period

• Expense Reduction: Total operating expenses decreased by approximately 35% (from $30.7M to $19.9M) primarily due to a pipeline prioritization strategy implemented in September 2024. This included a 49% workforce reduction and a suspension of enrollment in the INB-400 Phase 2 trial.
• Capital Raising: The company raised significant capital in late 2025, including $18.5 million from a private placement (December 2025) and $8.6 million from its At-The-Market (ATM) program, compared to $11.2 million from a private placement and $3.8 million from ATM in 2024.
• Stock Split: A 1-for-30 reverse stock split was executed in June 2025 to maintain Nasdaq listing compliance.
• Going Concern: Management and auditors have expressed substantial doubt regarding the company's ability to continue as a going concern. Cash on hand ($27.1M) is projected to fund operations only through April 2027.

Guidance, Outlook, and Risks

Clinical Pipeline Updates:

• INB-100 (Leukemia): Phase 1 expansion cohort ongoing; 100% of AML patients remained in complete remission as of Jan 2025. Long-term follow-up expected late 2026.
• INB-200/400 (Glioblastoma): Enrollment in Phase 2 (INB-400) suspended in Sept 2024 to conserve capital. Data showed median progression-free survival (mPFS) of 13.0 months vs. 6.6 months for standard of care. Further updates expected mid-to-late 2026.
• INB-619 (Autoimmune/Oncology): Preclinical TCE candidate showing deep B-cell depletion with favorable safety profile. Animal data presentation expected in 2026.

Outlook & Strategy: The company is focused on cash preservation, completing the INB-100 expansion, and seeking strategic partnerships or additional financing to advance INB-400 and INB-619. A second closing of the 2025 private placement (up to $20.1M) is contingent on achieving specific clinical and stock price milestones.

Key Risks:

• Liquidity: Substantial doubt exists regarding the ability to continue as a going concern without additional financing.
• Capital Constraints: Limited public float restricts the ability to raise capital via Form S-3 shelf registration (limited to 1/3 of public float).
• Development Risk: Clinical trials may fail to demonstrate efficacy or safety; regulatory approval is uncertain.
• Intellectual Property: Reliance on licensed IP from Emory University and UAB Research Foundation; failure to meet diligence obligations could result in termination of licenses.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the "April 2027" cash runway projection given current burn rates and potential inflation in clinical costs.
• Financing Triggers: Review the specific conditions for the second closing of the 2025 private placement (INB-619 animal data and stock price thresholds) to assess the likelihood of receiving the additional ~$20M.
• Warrant Dilution: Assess the potential dilution from outstanding pre-funded warrants (~9.7M) and Series B/C warrants, noting the low exercise prices ($0.0001 - $8.10).
• Clinical Data Validation: Scrutinize the independent validation of the INB-200/400 survival data (mPFS 13.0 months) compared to historical controls, as this is the primary value driver for potential partnerships.
• License Obligations: Confirm the company is meeting diligence milestones under the Emory and UABRF license agreements to avoid IP termination.